RNA

News

prnewswire.comAtrium Therapeutics Reports First Quarter 2026 Financial Resultsprnewswire.comMay 14

prnewswire.comAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaborationprnewswire.comApr 23

prnewswire.comAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.comApr 20

Trade RNA

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

CEO: Kathleen Gallagher
IPO Date: Feb 27, 2026

Market Data

Open: $11.60
High: $11.89
Low: $11.45
Volume: 200.5K
52W High: $16.77
52W Low: $11.45

Valuation

Market Cap: $201M
Enterprise Value: $-64M

Financials

Free Cash Flow: $-43M
Revenue: $19M
Net Income: $-77M
Cash: $270M
Debt: $3.7M

Events

EarningsSep 2

EPS est. -1.42